Trial · NCT07261683
Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
NCT07261683, Phase 2, Recruiting, Obstetrics & Gynecology Hospital of Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer. Trials, record NCT07261683. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07261683
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer
- NCT number
- NCT07261683
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Obstetrics & Gynecology Hospital of Fudan University
- Conditions
- Ovarian Cancer, Immunotherapy, Pembrolizumab
- Interventions
- Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron
- First posted
- 2025-12-03
- Last updated
- 2025-12-19
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | Month 6 | Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR). ORR was defined as the percentage of participants who had a Complete Response (Disappearance of all target lesions) or a Partial Response (≥30% decrease in the sum of the longest diameter of target lesions) using RECIST 1.1 based on BICR. |
| Secondary | Progression Free Survival (PFS) at 6 Months | Month 6 | PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1 PD was defined as ≥20% increase in SOD of target lesions and an absolute SOD increase of ≥5 mm. The appearance of ≥1 new lesion is also PD. PFS at 6 months is defined as the percentage of patient who was progression free at 6 months from the date of first study treatment. |
| Secondary | Overall Survival (OS) at 6 Months | Month 6 | OS at 6 months is defined as the percentage of patients who are alive at 6 months from the date of first study treatment. |
| Secondary | Progression Free Survival (PFS) at 12 Months | Month 12 | PFS was defined as the time from first dose of study treatment to the first documented progressive disease (PD) per RECIST 1.1 based on BICR, or death due to any cause, whichever occurred first. Per RECIST 1.1 PD was defined as ≥20% increase in SOD of target lesions and an absolute SOD increase of ≥5 mm. The appearance of ≥1 new lesion is also PD. PFS at 12 months is defined as the percentage of patient who was progression free at 12 months from the date of first study treatment. |
| Secondary | Overall Survival (OS) at 12 Months | Month 12 | OS at 12 months is defined as the percentage of patients who are alive at 12 months from the date of first study treatment. |
| Secondary | Incidence of grade 3-4 Adverse Events (AEs) | up to 1 month after the end of treatment | Incidence of grade 3-4 AEs, according to CTCAE, version 5.0 |
| Other | Exploratory outcome: biomarkers testing and efficacy of anti-tumor immunity | Baseline and 6 months from the the date of first study treatment | Biomarker testing for PD-L1 expression in exploratory analysis. |
| Other | Exploratory outcome: biomarkers testing and efficacy of anti-tumor immunity | Baseline and 6 months from the the date of first study treatment | Biomarker testing for BMI (weight and height will be combined to report BMI in kg/m\^2) in exploratory analysis. |
| Other | Exploratory outcome: biomarkers testing and efficacy of anti-tumor immunity | Baseline and 6 months from the the date of first study treatment | Biomarker testing for tumor microenvironment (including density and state of CD8+ T cells density and other immune cells) in exploratory analysis. |
| Other | Exploratory outcome: biomarkers testing and efficacy of anti-tumor immunity | Baseline and 6 months from the the date of first study treatment | Biomarker testing for circulating anti-tumor immunity (including density and state of CD8+ T cells density and other immune cells) in exploratory analysis. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07261683
GET https://conductscience.org/api/trials/v1/NCT07261683/registered